Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic drug monitoring of teriflunomide and fingolimod in multiple sclerosis
2022-004331-23Phase 4Completed
- Sponsor
- University Hospital Ostrava
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fingolimod and teriflunomide in multiple sclerosis (MS) (2 arms), sponsored by University Hospital Ostrava. Primary endpoint: Correlation of fingolimod and teriflunomide concentrations with clinical status. Started Jan 2023; status: completed.
02
Drugs
fingolimodteriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2022-004331-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004331-23.